XML 54 R40.htm IDEA: XBRL DOCUMENT
v3.24.0.1

STOCKHOLDERS' EQUITY (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Equity [Abstract] |
Schedule of business acquisitions, by acquisition | Stock issuances in relation to acquisitions during the years ended December 31, 2023, 2022 and 2021 were as follows:
(In thousands, except for per share data) |  | Period of Acquisition |  | Shares Issued |  | Fair Value of Shares Issued
OmicEra |  | May 2022 |  | 265,186 |  | $ | 14,792 |
PreventionGenetics |  | December 2021 |  | 1,070,410 |  | 84,252 |
Ashion |  | April 2021 |  | 125,444 |  | 16,224 |
Thrive |  | January 2021 |  | 9,323,266 |  | 1,191,420 |
TARDIS license |  | January 2021 |  | 191,335 |  | 27,263 |
The acquisition date fair value of the consideration transferred for Resolution Bioscience was approximately $54.2 million, which consisted of the following:
(In thousands) |  |
Cash |  | $ | 52,527 |
Fair value of replaced equity awards |  | 1,675 |
Total purchase price |  | $ | 54,202 |
The acquisition date fair value of the consideration transferred for OmicEra was approximately $19.4 million, which consisted of the following:
(In thousands) |  |
Common stock issued |  | $ | 14,792 |
Contingent consideration |  | 4,600 |
Cash paid related to working capital adjustment |  | 16 |
Total purchase price |  | $ | 19,408 |
The acquisition date fair value of the consideration transferred for PreventionGenetics was approximately $185.4 million, which consisted of the following:
(In thousands) |  |
Cash |  | $ | 101,129
Common stock issued |  | 84,252
Total purchase price |  | $ | 185,381
The acquisition date fair value of the consideration transferred for Ashion was approximately $110.0 million, which consisted of the following:
(In thousands) |  |
Cash |  | $ | 74,775
Common stock issued |  | 16,224
Contingent consideration |  | 19,000
Total purchase price |  | $ | 109,999
The acquisition date fair value of the consideration transferred for Thrive was approximately $2.19 billion, which consisted of the following:
(In thousands) |  |
Common stock issued |  | $ | 1,175,431
Cash |  | 584,996
Contingent consideration |  | 331,348
Fair value of replaced equity awards |  | 52,245
Previously held equity investment fair value |  | 43,034
Total purchase price |  | $ | 2,187,054
Schedule of amounts recognized in accumulated other comprehensive income (loss) (AOCI) | The amount recognized in AOCI for the years ended December 31, 2023, 2022 and 2021 were as follows:
(In thousands) |  | Cumulative Translation Adjustment |  | Unrealized Gain (Loss) on Securities (1) |  | AOCI
Balance at January 1, 2021 |  | $ | — |  |  | $ | 526 |  |  | $ | 526 |
Other comprehensive income (loss) before reclassifications |  | 23 |  |  | (1,648) |  |  | (1,625) |
Amounts reclassified from accumulated other comprehensive income (loss) |  | — |  |  | (514) |  |  | (514) |
Net current period change in accumulated other comprehensive loss |  | 23 |  |  | (2,162) |  |  | (2,139) |
Income tax benefit related to items of other comprehensive loss |  | — |  |  | 170 |  |  | 170 |
Balance at December 31, 2021 |  | $ | 23 |  |  | $ | (1,466) |  |  | $ | (1,443) |
Other comprehensive income (loss) before reclassifications |  | 30 |  |  | (4,049) |  |  | (4,019) |
Amounts reclassified from accumulated other comprehensive income (loss) |  | — |  |  | 226 |  |  | 226 |
Net current period change in accumulated other comprehensive loss |  | 30 |  |  | (3,823) |  |  | (3,793) |
Balance at December 31, 2022 |  | $ | 53 |  |  | $ | (5,289) |  |  | $ | (5,236) |
Other comprehensive income (loss) before reclassifications |  | 1,321 |  |  | 1,416 |  |  | 2,737 |
Amounts reclassified from accumulated other comprehensive income (loss) |  | — |  |  | 3,927 |  |  | 3,927 |
Net current period change in accumulated other comprehensive income (loss) |  | 1,321 |  |  | 5,343 |  |  | 6,664 |
Balance at December 31, 2023 |  | $ | 1,374 |  |  | $ | 54 |  |  | $ | 1,428 |
_________________________________ (1)There was no tax impact from the amounts recognized in AOCI for the years ended December 31, 2023 and 2022.
Schedule of amounts reclassified from accumulated other comprehensive income (loss) | Amounts reclassified from AOCI for the years ended December 31, 2023, 2022 and 2021 were as follows:
|  |  |  | Year Ended December 31,
Details about AOCI Components (In thousands) |  | Affected Line Item in the Statements of Operations |  | 2023 |  | 2022 |  | 2021
Change in value of available-for-sale investments |  |  |  |  |  |  |  |
Sales and maturities of available-for-sale investments |  | Investment income (loss) |  | $ | 3,927 |  |  | $ | 226 |  |  | $ | (514) |
Total reclassifications |  |  |  | $ | 3,927 |  |  | $ | 226 |  |  | $ | (514) |

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss). + References No definition available. + Details
Name: | us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the components of accumulated other comprehensive income (loss). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20 + Details
Name: | us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-3 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2 + Details
Name: | us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration